Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Rivian Automotive, Inc. (RIVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Rivian Automotive, Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $28.43 (market cap $5.07B), while Rivian Automotive, Inc. trades at $15.83 (market cap $23.06B). The key difference: Rivian Automotive, Inc. is far larger — about 4.5× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Rivian Automotive, Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | RIVN | |
|---|---|---|
Market Cap | $5.07B | $23.06B |
Sector | Health | Consumer Cyclical |
52-Week High | $29.45 | $22.45 |
52-Week Low | $20.06 | $12.06 |
Enterprise Value | $4.19B | $23.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $28.38, down 3.5% over the past day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with $0.18 EPS versus $0.07 expected, and raised its 2026 revenue outlook. Revenue growth has accelerated from $517M in 2022 to $1.07B in 2025, with net income turning positive in 2024 and reaching $391M in 2025.
The outlook remains positive with 70% analyst buy ratings and a $33.89 consensus price target, though risks include high RSI levels suggesting overbought conditions and dependence on key drug trials. Near-term catalysts include Phase 2 data for remlifanserin in Alzheimer's psychosis, expected by October 2026.
Rivian stock trades at $15.82, down 3.3% today, amid ongoing profitability challenges despite recent earnings beats. The company shows improving revenue trends with 2025 revenue reaching $5.39B, though net losses remain substantial at -$3.65B. Technical indicators signal bearish momentum with the stock trading near key support levels, while analyst sentiment remains cautiously optimistic with a $18.70 consensus target. Recent R2 vehicle launches and Uber partnership provide growth catalysts.
Rivian presents a high-risk, high-reward opportunity with significant cash burn offset by promising R2 ramp-up and delivery guidance increases. While improving margins and narrowing losses suggest progress, execution risks and capital needs remain substantial. The stock offers 18% upside to consensus targets but requires successful scaling and profitability milestones to justify current valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Rivian Automotive, Inc.
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →
